Related Experiment Videos
[Beta-blockers and obstructive pulmonary diseases: such an odd couple?]
O Grosgurin1, A Bria, J M Gaspoz
1Département de médecine interne, Service de médecine interne générale, HUG, Genève. olivier.grosgurin@hcuge.ch
Revue Medicale Suisse
|March 1, 2006
Summary
Beta-blockers can be safely prescribed to stable Chronic Obstructive Pulmonary Disease (COPD) patients with heart disease, improving survival. However, they are contraindicated in severe, decompensated COPD or poorly controlled asthma.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition often linked to smoking.
- COPD patients frequently have co-existing heart conditions that could benefit from beta-blocker treatment.
- There is apprehension regarding beta-blocker use in COPD due to potential bronchospasm risks, leading to under-prescription.
Purpose of the Study:
- To evaluate the safety and efficacy of beta-blocker therapy in patients with COPD and comorbid cardiac conditions.
- To identify appropriate patient selection criteria for beta-blocker use in this population.
Main Methods:
- Review of existing literature and clinical guidelines.
- Analysis of patient cohorts with COPD and cardiac comorbidities.
Main Results:
- Cardio-selective beta-blockers are generally safe and reduce mortality in stable COPD patients with cardiac disease.
- Beta-blockers are contraindicated in acute decompensated COPD with severe bronchospasm and poorly controlled asthma.
Conclusions:
- Careful patient selection is essential for beta-blocker therapy in COPD.
- Close clinical and functional monitoring is mandatory when prescribing beta-blockers to COPD patients.